Table 4

Characteristics of patients who would benefit from implanted cardioverter-defibrillator treatment*

*Derived from trial data and clinical evidence.10,21–26
EPS, electrophysiological study; LVEF, left ventricular ejection fraction; MI, myocardial infarction; VT, ventricular tachycardia.
Primary preventionPatients surviving cardiac arrest
Patients having symptomatic sustained ventricular tachyarrhythmias
Patients with symptomatic sustained ventricular tachyarrythmias and LVEF ≤40%
Secondary preventionPatients having underlying coronary heart disease with unsustained VT and inducible VT on EPS
Patients post MI with unsustained VT, LVEF ≤35% with inducible VT not suppressed by procaineamide with no indications for coronary artery surgery within 3 months
OtherLong QT syndrome
Brugada syndrome
Hypertropic obstructive cardiomyopathy